Patient Engagement

Antibacterial Drug Development
Topics Included: Data Collecting and Reporting, Ensuring Quality, Innovative Trials, Patient Engagement, Regulatory Submissions + Approvals, Safety
SHARE TO:
Overview
Increasing bacterial resistance coupled with decreasing research on new antibacterial drugs is creating a crisis that could disproportionately impact our most vulnerable populations, including children and the seriously ill.
CTTI has created approaches for streamlining antibacterial drug development that will help you design clinical trials that better assess the efficacy and safety of new antibacterial drugs and inform clinical trial planning, recruitment, enrollment, and feasibility. Use CTTI’s recommendations and resources to help combat this complex public health concern.
Projects
ABDD HABP/VABP STUDIES
Learn about CTTI’s prospective, multi-center, observational study of the risk factors for HABP/VABP.
ABDD PEDS TRIALS
Design pediatric antibacterial trials that ensure adequate enrollment, decrease the burden on sites and families, and increase engagement with healthcare providers.
ABDD STREAMLINING HABP/VABP TRIALS
Streamline protocol elements and data collection in HABP/VABP trials to increase enrollment, reduce trial complexity, and optimize operational efficiency.
ABDD UNMET NEED
Read about CTTI’s research findings on patient and physician perspectives and considerations as it relates to using antibacterial drugs developed through streamlined development processes.
Resources
Antibacterial Drug Development
Collective Strategies to Enhance Proportionate Enrollment
Patient Engagement Collaborative Announces Eight New Members
CTTI and FDA Convene Workshop on Including Patient Perspectives in Clinical Trials
CTTI Launches New Online Digital Health Trials Hub
CTTI Offers Path Forward for Using Decentralized Clinical Trials
CTTI and the FDA Select Representatives for Patient Engagement Collaborative
CTTI Selected to Support FDA Efforts to Increase Patient Engagement Through New Collaborative
Conducting Multi-Center Trials: New Recommendations and Tool for Research
Formats
Stage of Trial

Collective Strategies to Enhance Proportionate Enrollment
Topics Included: Access to Clinical Trials, Patient Engagement, Recruitment, Regulatory Submissions + Approvals, Site Planning
SHARE TO:
The Collective Strategies to Enhance Proportionate Enrollment project focuses on improving accountability, clarity, and communication across clinical trials partner groups to support more effective recruitment, enrollment, and retention practices. This effort seeks to understand and address the challenges, expectations, and needs of each group involved in clinical trials, including contract research organizations, patient organizations, sites, and sponsors.
By fostering action-focused and unified engagement throughout the clinical trials process, the project aims to identify practical solutions that help plan, design, and execute trials better positioned to recruit and retain participants who reflect the epidemiology and scientific evidence of the disease under study. These efforts will support the generation of reliable, relevant, and robust data to inform the development of safe and effective medical products for all populations.
Key Takeaways
Resources
Antibacterial Drug Development
Patient Engagement Collaborative Announces Eight New Members
CTTI and FDA Convene Workshop on Including Patient Perspectives in Clinical Trials
CTTI Launches New Online Digital Health Trials Hub
CTTI Offers Path Forward for Using Decentralized Clinical Trials
CTTI and the FDA Select Representatives for Patient Engagement Collaborative
CTTI Selected to Support FDA Efforts to Increase Patient Engagement Through New Collaborative
Conducting Multi-Center Trials: New Recommendations and Tool for Research
Formats
Stage of Trial

Patient Engagement Collaborative Announces Eight New Members

Topics Included: Patient Engagement
SHARE TO:
Today, the U.S. Food and Drug Administration (FDA) and the Clinical Trials Transformation Initiative (CTTI) announced eight newly selected representatives for the Patient Engagement Collaborative (PEC). The group of 16 caregivers, patients, and patient group representatives meets with the FDA several times a year and discusses a variety of topics such as improving communications, education, and patient engagement related to medical product regulation. Those selected to the PEC are expected to serve for two years.
The eight new representatives are:
- Bernard Coley
- Lisa Craine
- Rebecca Esparza
- Syreen Goulmamine
- Heather Guidone
- Carter Hemion
- Toni Jaudon
- Mary Anne Meskis
The representatives were selected from 75 applications received in response to a Federal Register notice published in July 2024. These new members of the PEC include caregivers who have personal experience supporting someone with a health condition, patients who have personal disease experience, and representatives from patient groups who have direct or indirect disease experience. The selection committee, which included FDA staff from multiple centers, CTTI staff and several outgoing PEC members, worked to identify individuals with diverse perspectives and experiences who could meaningfully contribute and express the patient voice.
The PEC, a collaboration established by the FDA and CTTI in 2018, is a group of patient organizations and individual representatives who discuss ways to enhance patient engagement. The FDA and CTTI collaborate to involve representatives with a variety of perspectives including caregivers, patients, and representatives from diverse patient organizations and communities. The PEC is run by the FDA’s Public Engagement Staff, which is responsible for communicating, educating, and engaging with external partners including academia, caregivers, consumers, health care providers, patients, and trade associations on the agency’s policy priorities.
Going forward, the PEC will continue the dialogue around how patient perspectives can inform the clinical trials enterprise and provide information and resources to enhance PEC members’ knowledge about the FDA and CTTI activities to share with patient communities. Previous topics have included: increasing awareness of existing engagement mechanisms among patients and patient groups; increasing patients’ education to empower them to act as representatives of their broader community; enhancing communication between the FDA and patient communities; and promoting global collaboration of patient organizations.
The FDA and CTTI wish to thank the outgoing members for their service to the PEC over the past several years:
- Kim Hindery
- Yasmin Ibrahim
- Seth Morgan
- Cara O’Neill
- Ceciel Rooker
- Christina Sisti
- Trina Stelly
- Lauren Youngborg
Since 2008, CTTI has included patient advocates on its Executive Committee, Steering Committee, and project teams and, today, nearly all of its more than 30 sets of evidence-based recommendations and associated frameworks and tools mention inclusion of patients as a critical part of the clinical trials process.
Recent News Feed
- FDA, CTTI Convening 2025 Hybrid Public Workshop on Artificial Intelligence in Drug & Biological Product Development August 25, 2025

- CTTI Releases New Recommendations to Guide Use of Disease Progression Modeling in Medical Product Development July 8, 2025

- Optimizing Flexibility and Data Quality in Clinical Trials: Bringing Clarity to DIA Global 2025 June 25, 2025

CTTI and FDA Convene Workshop on Including Patient Perspectives in Clinical Trials
[yoast-breadcrumb]
CTTI Project: Patient Group Engagement
The Clinical Trials Transformation Initiative (CTTI) will convene a public workshop, “Enhancing the Incorporation of Patient Perspectives in Clinical Trials," in collaboration with the U.S. Food and Drug Administration (FDA) on Mon., March 18, from 9:00 a.m. to 5:00 p.m. at the Tommy Douglas Conference Center in Silver Spring, Md.
Download Press Release (262.53 KB)
CTTI Launches New Online Digital Health Trials Hub
CTTI Project: Developing Novel Endpoints, Planning Decentralized Trials
Today the Clinical Trials Transformation Initiative (CTTI) announced a new online Digital Health Trials Hub featuring enhanced recommendations and additional resources.
CTTI Offers Path Forward for Using Decentralized Clinical Trials
[yoast-breadcrumb]
CTTI Project: Supporting Decentralized Trial Approaches
The Clinical Trials Transformation Initiative (CTTI) will unveil new recommendations to speed the use of decentralized clinical trials (DCTs)—trials run through telemedicine and mobile health care providers—today at the DPharm: Disruptive Innovations to Advance Clinical Trials conference in Boston, Mass.
Download Press Release (267.49 KB)
CTTI and the FDA Select Representatives for Patient Engagement Collaborative
CTTI Project: Patient Engagement Collaborative
The Clinical Trials Transformation Initiative (CTTI) and the U.S. Food and Drug Administration (FDA) announced newly selected representatives for the Patient Engagement Collaborative (PEC) today. The group of 16 patients, caregivers, and patient group representatives will meet with the FDA several times a year to discuss topics such as communication, transparency, and the best ways for patients to participate in the FDA’s regulatory discussions about medical products.
Download Press Release (280.48 KB)
CTTI Selected to Support FDA Efforts to Increase Patient Engagement Through New Collaborative
[yoast-breadcrumb]
CTTI Project: Patient Engagement Collaborative
CTTI has been engaged by the U.S. Food and Drug Administration (FDA) to support its Patient Engagement Collaborative (PEC), an effort created in partnership with CTTI to bring together members of the patient community to discuss the best ways for patients to participate in the FDA’s regulatory discussions about medical products.
Download Press Release (262.58 KB)
Conducting Multi-Center Trials: New Recommendations and Tool for Research
[yoast-breadcrumb]
CTTI Project: Supporting Decentralized Trial Approaches
A collaborative research team established by the Clinical Trials Transformation Initiative (CTTI) created a new tool and recommendations to improve the efficiency and quality of multi-center clinical trials.
Download Press Release (52.81 KB)